{"id":654051,"date":"2023-06-02T07:08:02","date_gmt":"2023-06-02T07:08:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=654051"},"modified":"2023-06-02T07:08:02","modified_gmt":"2023-06-02T07:08:02","slug":"iga-nephropathy-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20222032-states-delveinsight-key-companies-aravive-aduro-biotech-alnylam-chinook-therapeutic","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/iga-nephropathy-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20222032-states-delveinsight-key-companies-aravive-aduro-biotech-alnylam-chinook-therapeutic_654051.html","title":{"rendered":"IgA Nephropathy Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2022-2032), States DelveInsight | Key Companies – Aravive, Aduro BioTech, Alnylam, Chinook Therapeutic"},"content":{"rendered":"
\n
\"IgA<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
As per DelveInsight, the IgA Nephropathy Market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases of IgA Nephropathy and the launch of new therapies in the market. Some of the leading players in the IgA Nephropathy Market include Calliditas Therapeutics AB, Chinook Therapeutics, Inc., Novartis Pharmaceuticals, Omeros Corporation, Otsuka Pharmaceutical, RemeGen, Vera Therapeutics, and others.<\/div>\n

DelveInsight’s “IgA Nephropathy Market Insights, Epidemiology, and Market Forecast 2032<\/strong>” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the IgA Nephropathy market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, Japan, and China).<\/p>\n

The report covers emerging IgA Nephropathy drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current IgA Nephropathy treatment practice\/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

IgA Nephropathy: An Overview<\/strong><\/p>\n

IgA Nephropathy (IgAN) is an autoimmune disease that attacks the kidneys. It affects blood filtration in the small blood vessels of the kidneys. IgAN occurs when an abnormal protein damages the filtering unit (glomerulus) inside the kidneys.<\/p>\n

IgAN is the most common glomerular disease worldwide but varies largely geographically. Studies assess the prevalence of IgAN in different regions and analyze factors responsible for geographic differences. According to one such prominent study, IgAN is more frequent in Asian populations (45 cases per million population in Japan) than in Caucasians (31 cases per million population\/y in France).<\/p>\n

IgA Nephropathy Market Key Facts<\/strong><\/p>\n